Evidence map›Paper›PMID 35514087›Full record

Trial reportCardiology journal2024

The impact of mild therapeutic hypothermia on platelet reactivity in comatose survivors of cardiac arrest with acute myocardial infarction treated with ticagrelor.

Julia M Umińska, Jakub Ratajczak, Krzysztof Pstrągowski, Katarzyna Buszko, Klaudiusz Nadolny, Tomasz Fabiszak, Klemen Steblovnik, Marko Noč, Jacek Kubica

Open access · goldAbstract readObservational StudyClinical Trial, Phase IV
In one paragraph

Trial report in Cardiology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Julia M UmińskaDepartment of Geriatrics, Nicolaus Copernicus University, Torun, Poland. julia.uminska@cm.umk.pl.ORCID 0000-0003-2309-2369
Jakub RatajczakDepartment of Cardiology, Nicolaus Copernicus University, Torun, Poland.
Krzysztof PstrągowskiDepartment of Cardiology, Nicolaus Copernicus University, Torun, Poland.
Katarzyna BuszkoDepartment of Theoretical Foundations of Biomedical Science and Medical Informatics, Nicolaus Copernicus University, Torun, Poland.
Klaudiusz NadolnyFaculty of Medicine, University of Technology, Katowice, Poland.
Tomasz FabiszakDepartment of Cardiology, Nicolaus Copernicus University, Torun, Poland.
Klemen SteblovnikCenter for Intensive Internal Medicine, University Medical Center, Ljubljana, Slovenia.
Marko NočCenter for Intensive Internal Medicine, University Medical Center, Ljubljana, Slovenia.
Jacek KubicaDepartment of Cardiology, Nicolaus Copernicus University, Torun, Poland.ORCID 0000-0001-8250-754X
Nicolaus Copernicus University · PLLjubljana University Medical Centre · SIWSB University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of the study was to assess the antiplatelet effect of ticagrelor in patients with myocardial infarction (MI) after out-of-hospital cardiac arrest (OHCA) treated with percutaneous coronary intervention (PCI) and mild therapeutic hypothermia (MTH) vs. MI patients without OHCA treated with PCI.

methodsThe study was designed and performed as a phase IV, single-center, investigator-initiated, prospective, observational study assessing the early pharmacodynamic effect (within first 24 h) of a ticagrelor loading dose (180 mg) in both groups of patients (MTH group vs. MI group). For assessment of ticagrelor pharmacodynamics Multiple Electrode Aggregometry (MEA) was applied.

resultsCompared with the MTH group, platelet inhibition was persistently stronger in the MI group over the entire observation period (up to 24 h), with the highest differesnce at 4 hours after loading with ticagrelor (25.8 ± 26.4 vs. 75.8 ± 40.9 U, p = 0.002). As a consequence, there was a higher prevalence of high platelet reactivity in the MTH group, with the most explicit difference at 6 hours after the loading dose of ticagrelor (78% vs. 7%, p < 0.001).

conclusionsIn comparison with patients treated with primary PCI for uncomplicated MI, the antiplatelet effect of ticagrelor in patients with MI complicated with OHCA, undergoing MTH and primary PCI, is attenuated and delayed.

Indexed as

Blood PlateletsComaHypothermia, InducedMyocardial InfarctionOut-of-Hospital Cardiac ArrestPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsTicagrelorAgedFemaleHumansMaleMiddle AgedPlatelet AggregationPlatelet Function TestsProspective StudiesPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsTicagrelorcardiac arresthypothermiamyocardial infarctionpharmacodynamicplateletsticagrelor

Identifiers

PMID35514087
PMCPMC11229810
OpenAlexW4229019928

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.